Lead Product(s) : FT-003
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-003 is a gene therapy product for the treatment of neovascular age-related macular degeneration. It has the potential to provide durable expression of therapeutic levels of intraocular protein and maintaining the vision of patients.
Product Name : FT-003
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : FT-003
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FT-001
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001
Details : Frontera’s FT-001 is an AAV gene therapy product administered by a one-time injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene to the nuclei of the patient’s retinal cells.
Product Name : FT-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : FT-001
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
